Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.48 |
| ▸ | CSNK1D | P48730 | 8/20 | 0.47 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ACP1 | P24666 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | LCK | P06239 | 1/20 | 0.43 |
| ▸ | ITK | Q08881 | 1/20 | 0.43 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30265204 | 1.00 | DYRK1A (0.48) | DYRK1ACSNK1DPIK3CGKMT2AACP1 | |
| SCHEMBL2352223 | 0.87 | DYRK1A (0.52) | DYRK1ACSNK1DPIK3CGACP1CYP2D6 | |
| SCHEMBL17802787 | 0.85 | DYRK1A (0.51) | DYRK1ACSNK1DKMT2AACP1KDM4E | |
| SCHEMBL30265114 | 0.84 | KMT2A (0.55) | DYRK1AKMT2AKDM4ETDP1ALDH1A1 | |
| SCHEMBL2251888 | 0.83 | DYRK1A (0.50) | DYRK1ACSNK1DACP1KDM4ETDP1 | |
| SCHEMBL2249738 | 0.83 | DYRK1A (0.49) | DYRK1ACSNK1DACP1ALDH1A1MAPT | |
| SCHEMBL2248868 | 0.82 | SMN1; SMN2 (0.51) | DYRK1ACSNK1DPIK3CGKMT2AACP1 | |
| SCHEMBL2247719 | 0.81 | DYRK1A (0.48) | DYRK1ACSNK1DACP1ALDH1A1MAPT | |
| SCHEMBL2248676 | 0.78 | ACSS2 (0.47) | DYRK1ACSNK1DACP1RAB9A | |
| SCHEMBL29602968 | 0.78 | ACSS2 (0.47) | DYRK1ACSNK1DACP1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210069159-A1 | Bach1 Inhibitors in Combination with Nrf2 Activators and Pharmaceutical Compositions Thereof | VTV THERAPEUTICS LLC | 2021-03-11 | — | — | US | disclosed |
| US-10898475-B2 | Bach1 inhibitors in combination with Nrf2 activators and pharmaceutical compositions thereof | VTV THERAPEUTICS LLC (US) | 2021-01-26 | — | — | US | disclosed |
| US-10463652-B2 | Bach1 inhibitors in combination with Nrf2 activators and pharmaceutical compositions thereof | VTV THERAPEUTICS LLC (US) | 2019-11-05 | — | — | US | disclosed |
| US-20190076410-A1 | Bach1 Inhibitors in Combination with Nrf2 Activators and Pharmaceutical Compositions Thereof | VTV THERAPEUTICS LLC | 2019-03-14 | — | — | US | disclosed |
| US-10172840-B2 | Bach1 inhibitors in combination with Nrf2 activators and pharmaceutical compositions thereof | VTV THERAPEUTICS LLC (US) | 2019-01-08 | — | — | US | disclosed |
| US-20170231967-A1 | Bach1 Inhibitors in Combination with Nrf2 Activators and Pharmaceutical Compositions Thereof | VTV THERAPEUTICS LLC | 2017-08-17 | — | — | US | disclosed |
| WO-2016089648-A1 | BACH 1 INHIBITORS IN COMBINATION WITH NRF2 ACTIVATORS AND PHARMACEUTICAL COMPOSITIONS THEREOF | VTV THERAPEUTICS LLC (US) | 2016-06-09 | — | — | WO | disclosed |
| EP-2536285-A1 | SUBSTITUTED FUSED IMIDAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | High Point Pharmaceuticals, LLC (US) | 2012-12-26 | — | — | EP | disclosed |
| WO-2011103018-A1 | SUBSTITUTED FUSED IMIDAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10463652-B2 | Bach1 inhibitors in combination with Nrf2 activators and pharmaceutical compositions thereof | BACH1, KEAP1, NFE2L2 | DYRK1A 3015/4885CSNK1D 2078/4885PIK3CG 2842/4885 |
| US-20190076410-A1 | Bach1 Inhibitors in Combination with Nrf2 Activators and Pharmaceutical Compositions Thereof | BACH1, KEAP1, NFE2L2 | DYRK1A 3015/4885CSNK1D 2078/4885PIK3CG 2842/4885 |
| US-20170231967-A1 | Bach1 Inhibitors in Combination with Nrf2 Activators and Pharmaceutical Compositions Thereof | BACH1, KEAP1, NFE2L2 | DYRK1A 3015/4885CSNK1D 2078/4885PIK3CG 2842/4885 |
| US-10898475-B2 | Bach1 inhibitors in combination with Nrf2 activators and pharmaceutical compositions thereof | BACH1, KEAP1, NFE2L2 | DYRK1A 3704/4885CSNK1D 2154/4885PIK3CG 2863/4885 |
| US-20210069159-A1 | Bach1 Inhibitors in Combination with Nrf2 Activators and Pharmaceutical Compositions Thereof | BACH1, KEAP1, NFE2L2 | DYRK1A 2930/4885CSNK1D 2060/4885PIK3CG 2017/4885 |
| US-10172840-B2 | Bach1 inhibitors in combination with Nrf2 activators and pharmaceutical compositions thereof | BACH1, KEAP1, NFE2L2 | DYRK1A 3015/4885CSNK1D 2078/4885PIK3CG 2842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.